- OnLume Surgical, a Madison, Wis.-based medical device company developing novel imaging systems for use during surgery, closed a $7m Series A funding
- The round was led by Cambridge Investment Group (Luzich Partners LLC) with participation from WARF Ventures and Wisconsin Investment Partners (WIP)
- The company intends to use the funds to execute its plans for commercial launch
- OnLume is a surgical device company which recently received its first FDA regulatory clearance to bring its fluorescence-guided surgery (FGS) imaging system to market
- The technology cleared for fluorescence imaging of blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, reconstructive and microsurgeries
- OnLume is developing further applications of its imaging platform, including FGS for cancer surgery in which tumor-specific drugs could deliver fluorescent agents to cancer cells